How many insider trades does FilingIQ track for BCAB?

FilingIQ tracks 329 Form 4 insider transactions for BCAB (BioAtla, Inc.), covering filings from Dec 18, 2020 onwards. 7 of those were filed in the last 90 days.

Are BCAB insiders net buyers or net sellers?

Across the full Form 4 history for BCAB, 21 transactions (6%) were open-market purchases and 104 (32%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does BCAB insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is BCAB in?

BioAtla, Inc. (BCAB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $15.15M.

BCAB insider trading

NasdaqCM Healthcare

BioAtla, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

329

Last 90 days

Buys / sells

6% / 32%

Market cap

$15.15M

About BioAtla, Inc.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Company website: www.bioatla.com

BCAB insider activity at a glance

FilingIQ has scored 329 insider transactions for BCAB since Dec 18, 2020. The most recent filing in our index is dated Mar 11, 2026.

Across the full history, 21 open-market purchases and 104 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on BCAB insider trades is 56.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live BCAB trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for BCAB?: FilingIQ tracks 329 Form 4 insider transactions for BCAB (BioAtla, Inc.), covering filings from Dec 18, 2020 onwards. 7 of those were filed in the last 90 days.
Are BCAB insiders net buyers or net sellers?: Across the full Form 4 history for BCAB, 21 transactions (6%) were open-market purchases and 104 (32%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BCAB insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BCAB in?: BioAtla, Inc. (BCAB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $15.15M.

Methodology & sources

Every BCAB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.